EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives

Sunitha Vimalesvaran, Pietro Vajro, Anil Dhawan

Hepatology International · 2024-10 · 18 (S2) · 873-883

DOI: 10.1007/s12072-024-10691-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hepatology International, online erschienen am 16.06.2024. Verfasst von Sunitha Vimalesvaran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Liver, Gastroenterology and Nutrition Centres, King's College Hospital NHS Trust, London, UK. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The historical use of the term non-alcoholic fatty liver disease (NAFLD) in obese/overweight children has been controversial as to the appropriateness of this terminology in children, and lately, in adults too. Newer game-changer terminology, metabolic (dysfunction)-associated fatty liver disease (MAFLD), for this condition signifies a positive step forward that addresses the limitations of the previous definition for both adults and children. The prevalence of MAFLD has surged in tandem with the global rise in obesity rates, establishing itself as a predominant cause of chronic liver disease in both adult and pediatric populations. The adoption of the recently proposed nomenclature reflects a more encompassing comprehension of the disease and its etiology compared to its predecessor, NAFLD. Notably, the revised terminology facilitates the recognition of MAFLD as an autonomous condition while acknowledging the potential coexistence of other systemic fatty liver disorders. Particularly in children, this includes various paediatric-onset genetic and inherited metabolic disorders, necessitating thorough exclusion, especially in cases where weight loss interventions yield no improvement or in the absence of obesity. MAFLD presents as a multifaceted disorder; evidence suggests its origins lie in a complex interplay of nutritional, genetic, hormonal, and environmental factors. Despite advancements, current non-invasive diagnostic biomarkers exhibit limitations in accuracy, often necessitating imaging and histological evaluations for definitive diagnosis. While dietary and lifestyle modifications stand as cornerstone measures for MAFLD prevention and management, ongoing evaluation of therapeutic agents continues. This article provides an overview of the latest developments and emerging therapies in the realm of paediatric MAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansChildPediatric Obesity

Stichwörter der Autor:innen

AdolescentsChildrenDietFatty liver diseaseGut microbiomeLifestyleMetabolic (dysfunction)-associated fatty liver disease (MAFLD)Non-alcoholic fatty liver disease (NAFLD)NutritionObesityWeight loss

Autor:innen und Institutionen

  • Paediatric Liver, Gastroenterology and Nutrition Centres, King's College Hospital NHS Trust, London, UK.
  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Section of Pediatrics, Baronissi, Salerno, Italy.
  • Paediatric Liver, Gastroenterology and Nutrition Centres, King's College Hospital NHS Trust, London, UK. Anil.dhawan@nhs.net.

Zitieren

APA

Vimalesvaran, S., Vajro, P., & Dhawan, A. (2024). Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Hepatology International, 18(S2), 873-883. https://doi.org/10.1007/s12072-024-10691-5

Vancouver

Vimalesvaran S, Vajro P, Dhawan A. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Hepatology International. 2024;18(S2):873-883. doi:10.1007/s12072-024-10691-5

BibTeX
@article{Vimalesvaran2024,
  author = {Vimalesvaran, Sunitha and Vajro, Pietro and Dhawan, Anil},
  title = {Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives},
  journal = {Hepatology International},
  year = {2024},
  volume = {18},
  number = {S2},
  pages = {873--883},
  doi = {10.1007/s12072-024-10691-5}
}
Kostenlos starten →